ArticleInternational journal of implant dentistry2025
Horizontal vascular-stalked split osteotomy (HVSO): a bone augmentation technique for the atrophic jaw- a retrospective cohort study in 29 patients.
Article in International journal of implant dentistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImplant therapy in the advanced atrophic jaw remains challenging in oral and maxillofacial surgery. Hence, a plethora of different augmentation procedures to increase bone volume in the maxilla and mandible have been published. Horizontal vascular-stalked split osteotomy (HVSO) represents a safe and effective approach for the three-dimensional jaw augmentation since it combines maximum vascularization through lingual or palatinal periosteal stalking with reduced grafting morbidity.
objectiveTo analyze the efficacy of HVSO for implantation therapy in atrophic jaws by assessing vertical bone gain and implant survival rates. MATERIALS AND
methodsA total of n = 29 patients (14 females, 15 males) with a mean age of 55.4 ± 10.0 years and reduced volume of the alveolar ridge were retrospectively analyzed after treatment with 34 HVSOs in the maxilla and mandible. After controlled clinical follow-up of six months after augmentation, enossal implantation of 79 implants (maxilla 45, mandible 34) was performed. A standardized two-dimensional radiological assessment with panoramic tomography (OPTG) of the augmented bone height and clinical evaluation of the implants was performed over a mean follow-up period of 2.3 years.
resultsHVSO resulted in a significant increase in vertical bone height by 4.4 mm ± 2.0 mm (mean vertical gain: +59.4%) with + 101% in the maxilla and + 27.5% in the mandible directly after the procedure (T1), with both p < 0.001. After a mean observation period of 2.3 years bone height remained stable with a total gain of 41.4% (maxilla: 72.6%, mandible: 18.6%), with p < 0.001 and p = 0.001, respectively. Overall implant survival rate was 91% (maxilla: 89%; mandible: 94%).
conclusionHVSO reliably supports significantly enhanced vertical bone height with long-term stable results, thereby facilitating successful implantation in atrophic jaws with high implant survival rates observed over an extended follow-up period. CLINICAL TRIAL NUMBER: Not applicable as the study was no clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.